IL265829B - Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors - Google Patents
Quinoxaline compounds as type iii receptor tyrosine kinase inhibitorsInfo
- Publication number
- IL265829B IL265829B IL265829A IL26582919A IL265829B IL 265829 B IL265829 B IL 265829B IL 265829 A IL265829 A IL 265829A IL 26582919 A IL26582919 A IL 26582919A IL 265829 B IL265829 B IL 265829B
- Authority
- IL
- Israel
- Prior art keywords
- tyrosine kinase
- kinase inhibitors
- type iii
- receptor tyrosine
- iii receptor
- Prior art date
Links
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 title 1
- 125000001567 quinoxalinyl group Chemical class N1=C(C=NC2=CC=CC=C12)* 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
- C07D241/52—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662406328P | 2016-10-10 | 2016-10-10 | |
| PCT/US2017/055809 WO2018071348A1 (en) | 2016-10-10 | 2017-10-09 | Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL265829A IL265829A (en) | 2019-06-30 |
| IL265829B true IL265829B (en) | 2022-06-01 |
Family
ID=61905910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL265829A IL265829B (en) | 2016-10-10 | 2019-04-04 | Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10689362B2 (enExample) |
| EP (1) | EP3523285A4 (enExample) |
| JP (1) | JP7206188B2 (enExample) |
| KR (1) | KR102609813B1 (enExample) |
| CN (1) | CN110325515B (enExample) |
| AU (1) | AU2017342928B2 (enExample) |
| BR (1) | BR112019007271A2 (enExample) |
| CA (1) | CA3039919A1 (enExample) |
| IL (1) | IL265829B (enExample) |
| RU (1) | RU2019113764A (enExample) |
| SG (1) | SG11201903091VA (enExample) |
| TW (1) | TWI648266B (enExample) |
| WO (1) | WO2018071348A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4214198A4 (en) * | 2020-09-21 | 2024-10-09 | Hutchison Medipharma Limited | Heteroaromatic compounds and uses thereof |
| JP2024515976A (ja) * | 2021-04-26 | 2024-04-11 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 骨格再生のための機能不全骨格幹細胞の生化学的活性化 |
| WO2023082145A1 (en) * | 2021-11-11 | 2023-05-19 | 4B Technologies (Suzhou) Limited | Intermediate compound of quinoxaline and preparation process thereof |
| CN114605391B (zh) * | 2022-02-21 | 2024-01-26 | 广州六顺生物科技股份有限公司 | 喹喔啉类衍生物及其制备方法和应用 |
| CN115141177B (zh) * | 2022-08-30 | 2022-12-09 | 福贝生物科技(苏州)有限公司 | 喹喔啉类化合物马来酸盐的新晶型及其制备方法 |
| WO2025019622A2 (en) * | 2023-07-18 | 2025-01-23 | Elixiron Immunotherapeutics Inc. | Method of enhanced absorption of quinoxaline type iii receptor tyrosine kinase inhibitors |
| WO2025067450A1 (zh) * | 2023-09-28 | 2025-04-03 | 福贝生物医药科技(北京)有限公司 | 一种固体分散体、药物组合物、其制备方法及其用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0860433B1 (en) * | 1995-11-07 | 2002-07-03 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same |
| WO2000023444A1 (en) * | 1998-10-21 | 2000-04-27 | Abbott Laboratories | 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds |
| US7304092B1 (en) * | 2002-11-12 | 2007-12-04 | Yale University | Compounds and methods for treating tumors, cancer and hyperproliferative diseases |
| FR2856686A1 (fr) * | 2003-06-25 | 2004-12-31 | Sod Conseils Rech Applic | Benzothiazole-4,7-diones et benzooxazole-4,7-diones substituees en position 5 ou 6 et leurs procedes de preparation |
| GB0509227D0 (en) * | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Intracellular enzyme inhibitors |
| CN101432281B (zh) * | 2006-04-19 | 2013-08-28 | 诺瓦提斯公司 | 6-0-取代的苯并*唑和苯并噻唑化合物以及抑制csf-1r信号传导的方法 |
| JP5328640B2 (ja) * | 2006-04-19 | 2013-10-30 | ノバルティス アーゲー | ６−ｏ−置換ベンゾオキサゾールおよびベンゾチアゾール化合物ならびにｃｓｆ−１ｒシグナル伝達を阻害する方法 |
| WO2008063888A2 (en) * | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| NZ588511A (en) * | 2008-05-23 | 2012-04-27 | Novartis Ag | Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors |
| EP2473498A1 (en) * | 2009-09-04 | 2012-07-11 | Bayer Pharma Aktiengesellschaft | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors |
| GB201007286D0 (en) * | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201020179D0 (en) * | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| GB201118654D0 (en) * | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| EP2806874B1 (en) * | 2012-01-25 | 2017-11-15 | Neupharma, Inc. | Quinoxaline-oxy-phenyl derivatives as kinase inhibitors |
| PL2840080T3 (pl) * | 2012-04-17 | 2018-06-29 | Fujifilm Corporation | Zawierający azot związek heterocykliczny lub jego sól |
| WO2014075077A1 (en) * | 2012-11-12 | 2014-05-15 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| WO2016077632A2 (en) * | 2014-11-13 | 2016-05-19 | Buck Institute For Research On Aging | Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications |
-
2017
- 2017-10-09 EP EP17859434.7A patent/EP3523285A4/en active Pending
- 2017-10-09 SG SG11201903091VA patent/SG11201903091VA/en unknown
- 2017-10-09 RU RU2019113764A patent/RU2019113764A/ru not_active Application Discontinuation
- 2017-10-09 CA CA3039919A patent/CA3039919A1/en active Pending
- 2017-10-09 BR BR112019007271A patent/BR112019007271A2/pt not_active Application Discontinuation
- 2017-10-09 WO PCT/US2017/055809 patent/WO2018071348A1/en not_active Ceased
- 2017-10-09 CN CN201780075303.1A patent/CN110325515B/zh active Active
- 2017-10-09 KR KR1020197012725A patent/KR102609813B1/ko active Active
- 2017-10-09 AU AU2017342928A patent/AU2017342928B2/en active Active
- 2017-10-09 US US16/340,685 patent/US10689362B2/en active Active
- 2017-10-09 JP JP2019519329A patent/JP7206188B2/ja active Active
- 2017-10-11 TW TW106134711A patent/TWI648266B/zh active
-
2019
- 2019-04-04 IL IL265829A patent/IL265829B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN110325515B (zh) | 2023-06-20 |
| IL265829A (en) | 2019-06-30 |
| TWI648266B (zh) | 2019-01-21 |
| KR102609813B1 (ko) | 2023-12-07 |
| CN110325515A (zh) | 2019-10-11 |
| JP2019530708A (ja) | 2019-10-24 |
| TW201817720A (zh) | 2018-05-16 |
| WO2018071348A1 (en) | 2018-04-19 |
| CA3039919A1 (en) | 2018-04-19 |
| RU2019113764A (ru) | 2020-11-13 |
| US20190308949A1 (en) | 2019-10-10 |
| EP3523285A1 (en) | 2019-08-14 |
| KR20190059959A (ko) | 2019-05-31 |
| AU2017342928B2 (en) | 2021-09-09 |
| EP3523285A4 (en) | 2020-04-22 |
| JP7206188B2 (ja) | 2023-01-17 |
| US10689362B2 (en) | 2020-06-23 |
| RU2019113764A3 (enExample) | 2021-01-29 |
| BR112019007271A2 (pt) | 2019-09-17 |
| SG11201903091VA (en) | 2019-05-30 |
| AU2017342928A1 (en) | 2019-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279258B (en) | tyrosine kinase inhibitors | |
| HUS2400003I1 (hu) | Kináz inhibitorként alkalmas vegyületek | |
| IL268614A (en) | Aminotriazolopyridines as kinase inhibitors | |
| ZA201807179B (en) | Pyrimidine compounds as jak kinase inhibitors | |
| HUE057733T2 (hu) | Neuropátiás faktor tirozinkináz receptor inhibitorként alkalmazott amino-pirazolopirimidin vegyület | |
| IL265829B (en) | Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors | |
| IL274207A (en) | Aminoimidazopyridazines as kinase inhibitors | |
| IL255750A (en) | Heterocyclic compounds as kinase inhibitors | |
| EP3145512A4 (en) | Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors | |
| IL266789A (en) | Heterocyclic compounds as kinase inhibitors | |
| EP3448852A4 (en) | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF TYROSINE KINASE BCR-ABL | |
| IL266150A (en) | Amide compounds as kinase inhibitors | |
| HK40037119A (en) | Pyrimidine compounds useful as tyrosine kinase inhibitors | |
| EP3727387A4 (en) | PYRIMIDINE COMPOUNDS USEFUL AS TYROSINE KINASE INHIBITORS | |
| GB201613945D0 (en) | Compounds useful as kinase inhibitors | |
| GB201522245D0 (en) | Compounds useful as kinase inhibitors |